QUOTES THAT MATTER- not faceless non holding posters.
"Remestemcel-L suppresses activity of allo-reactive T cells that are causing a hyperinflammatory state and attacking various tissue in GVHD. I have seen remestemcel-L cure children with acute GvHD who have failed to respond to all standard therapies. I sincerely hope that this BLA is approved by the FDA with this resubmission," Joanne Kurtzberg, MD, professor of pediatrics and pathology, director of Marcus Center for Cellular Cures, Pediatric Blood and Marrow Transplant Program, and Carolinas Cord Blood Bank, and co-director, of Stem Cell Transplant Laboratory Duke University Medical Center, told Targeted OncologyTM.
Reg
- Forums
- ASX - By Stock
- MSB
- Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L
Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L, page-969
-
- There are more pages in this discussion • 39 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
96.5¢ |
Change
-0.005(0.52%) |
Mkt cap ! $1.107B |
Open | High | Low | Value | Volume |
98.0¢ | 98.5¢ | 96.0¢ | $1.139M | 1.172M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
29 | 189287 | 96.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
96.5¢ | 48393 | 16 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
29 | 189287 | 0.960 |
14 | 103935 | 0.955 |
15 | 275027 | 0.950 |
8 | 582647 | 0.945 |
9 | 99808 | 0.940 |
Price($) | Vol. | No. |
---|---|---|
0.965 | 48393 | 16 |
0.970 | 130191 | 19 |
0.975 | 225084 | 15 |
0.980 | 327409 | 19 |
0.985 | 100249 | 10 |
Last trade - 11.47am 13/08/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Steven Gourlay, Managing Director and CEO
Steven Gourlay
Managing Director and CEO
SPONSORED BY The Market Online